Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma
Robert Korngold(Georgetown University), Michèle L. Donato(The University of Texas Health Science Center at Houston), Phyllis McKiernan(Hackensack University Medical Center), Harlan Robins(Adaptive Biotechnologies (United States)), David S. Siegel(Hackensack Meridian Health), Themba Nyirenda(Hackensack University Medical Center), Ryan Emerson(Adaptive Biotechnologies (United States)), Marissa Vignali(Adaptive Biotechnologies (United States)), Kira Goldgirsh(Hackensack University Medical Center), Julie Rubinstein(Adaptive Biotechnologies (United States))
Cited by 2
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
|Nature Medicine|2018|927